期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

沙利度胺联合环磷酰胺和地塞米松治疗复发难治多发性骨髓瘤 被引量：7

Combination Chemotherapy of Thalidomide Cyclophosphamide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
暂未订购
导出
摘要 回顾分析36例复发、难治多发性骨髓瘤(MM)患者中沙利度胺、环磷酰胺、地塞米松(CTD)联合化疗的疗效及不良反应。7例(19.5%)完全缓解(CR),19例(52.8%)部分缓解(PR),3例(8.3%)微小缓解(MR),3例(8.3%)病情稳定(SD),4例(11.1%)疾病进展。总反应率为80.6%。认为该治疗不良反应较小,患者耐受性好。
作者 李迎春 张嵘 王慧涵 杨莹 朱珂 吴斌 姚鲲 廖爱军 杨威 刘卓刚
机构地区 中国医科大学附属盛京医院血液科
出处 《中国医科大学学报》 CAS CSCD 北大核心 2013年第6期564-566,共3页 Journal of China Medical University
基金 辽宁省科学技术计划项目(2010225032)
关键词 多发性骨髓瘤 复发 难治 沙利度胺
分类号 R552 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献5

二级参考文献24

  • 1Alexanian R, Haut A, Khan Au, et al. Treatment for multiple myelo-ma,combimation chemotherapy with different melphalan dose regi- mens[J]. JAMA, 1969,208(9): 1680-1685.
  • 2Singhal S, Mehta J, Desikan R, et al. Antitumoractivity of thalidomide in refractory muhiple myeloma [ J ]. N Eng J Med, 1999,341 (21) : 1565-1571.
  • 3Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myelomal : 10 years later [J]. Blood, 2008,111 (8) : 3968 - 3977.
  • 4Hulin C,Facon T,Rodon P,et al. Efficacy of melphalan and pred- nisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma:IFM 01/01 Trial [J]. J Clin Oncol, 2009,27(22) : 3664-3670.
  • 5KANE RC,BROSS PF,FARRELL AT,et al. Velcade: U.S.FDA approval for the treatment of multiple myeloma progressing on prior therapy [ J ].Oncologist, 2003,8(6) : 508-513.
  • 6GREIPP PR, SAN MIGUEL, DURIE BG, et al.International staging system for multiple myeloma [ J].J Clin Oncol, 2005,23 (15) : 3412- 3420.
  • 7BLADE J,SAMSON D,REECE D,et al.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation[ J].Br J Haematol, 1998,102(5 ) : 1115-1123.
  • 8PARAMORE A,FRANTZ S.Bortezomib [J].Nat Rev Drug Discov, 2003,2(8):611-612.
  • 9ANTONIO PALUMBO,MARIA TERESA AMBROSINI. Bortezomib, melphalan,prednisone,and thalidomide for relapsed multiple myeloma [ J].Blood, 2007(109) :2767-2772.
  • 10RICHARDSON PG,BARLOGIE B,BERENSON J,et al.A Phase 2 study of bortezomib in relapsed refractory myeloma [J].N Engl J Med, 2003,348 : 2609-2617.

共引文献11

同被引文献64

  • 1Lee A Y,Levine M N.Venous thromboembolism and cancer:Risks and outcomes[J] .Circulation,2003,107 (23Supple 1):117-121.
  • 2Musallam K M,Dahdaleh F S,Shamseddine A l,et al.Incidence and prophylaxis of venous thromboembolic events in multiplemveloma patients receiving immunomodulatory therapy[J] .Tbromb Res,2009,123(5):679-686.
  • 3Zangari M,Tricot G,Polavaram L,et al.Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone[J] .J Clin Oncol,2010,28(1):132-135.
  • 4Smith R A,Cokkinides V,Eyre H J.American Cancer Society guidelines for the early detection of cancer,2006[J] .CA Cancer J Clin,2006,56(1):11-25.
  • 5Shimizu K,Itoh J.A possible link between Trousseau's syndrome and tissue factor producing plasma cells[J] .Am J Hematol,2009,84(6):382-385.
  • 6Auwerda J J,Sonneveld P,de Maat M P,et al.Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma[J] .Haematologica,2007,92(2):279-280.
  • 7De Lucia D,De Vita F,Orditura M,et al.Hypercoagulable state in patients with advanced gastrointestinal cancer:evidence for an acquired resistance to activated protein C[J] .Tumori,1997,83(6):948-952.
  • 8Green D,Maliekel K,Sushko E,et al.Activated protein C resistance in cancer patients[J] .Haemostasis,1997,27(3):112-118.
  • 9Haim N,Lanir N,Hoffman R,et al.Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism[J] .Am J Med,2001,110(2):91-96.
  • 10Zangari M,Saghafifar F,Mehta P,et al.The blood coagulation mechanism in multiple myeloma[J] .Semin Thromb Hemost,2003,29(3):275-282.

引证文献7

二级引证文献20

中国医科大学学报
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部